Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus by Langer, Rupert et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Expression and clinical significance of Glucose Regulated Proteins 
GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the 
esophagus
Rupert Langer*1, Marcus Feith2, Joerg Rüdiger Siewert2, Hans-Juergen Wester3 
and Heinz Hoefler1,4
Address: 1Institute of Pathology, TU München, München, Germany, 2Department of Surgery, TU München, München, Germany, 3Department of 
Nuclear Medicine TU München, München, Germany and 4Institutes of Pathology, HGF – National Research Center for Environment and Health 
München, München, Germany
Email: Rupert Langer* - Rupert.Langer@lrz.tu-muenchen.de; Marcus Feith - feith@chir.med.tu-muenchen.de; 
Joerg Rüdiger Siewert - siewert@chir.med.tu-muenchen.de; Hans-Juergen Wester - H.J.Wester@lrz.tu-muenchen.de; 
Heinz Hoefler - hoefler@lrz.tu-muenchen.de
* Corresponding author    
Abstract
Background: Glucose regulated proteins (GRPs) are main regulators of cellular homeostasis due to their role as molecular
chaperones. Moreover, the functions of GRPs suggest that they also may play important roles in cancer biology. In this study we
investigated the glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in a series of human esophageal adenocarcinomas
to determine their implications in cancer progression and prognosis.
Methods: Formalin-fixed, paraffin-embedded tissues of primary resected esophageal (Barrett) adenocarcinomas (n = 137) and
corresponding normal tissue were investigated. mRNA-gene expression levels of GRP78 and GRP94 were determined by
quantitative real-time RT-PCR after mRNA extraction. Protein expression analysis was performed with immunohistochemical
staining of the cases, assembled on a tissue micorarray. The results were correlated with pathologic features (pT, pN, G) and
overall survival.
Results: GRP78 and GRP94 mRNA were expressed in all tumors. The relative gene expression of GRP78 was significantly
higher in early cancers (pT1m and pT1sm) as compared to more advanced stages (pT2 and pT3) and normal tissue (p = 0.031).
Highly differentiated tumors showed also higher GRP78 mRNA levels compared to moderate and low differentiated tumors (p
= 0.035). In addition, patients with higher GRP78 levels tended to show a survival benefit (p = 0.07). GRP94 mRNA-levels
showed no association to pathological features or clinical outcome.
GRP78 and GRP94 protein expression was detectable by immunohistochemistry in all tumors. There was a significant
correlation between a strong GRP78 protein expression and early tumor stages (pT1m and pT1sm, p = 0.038). For GRP94 low
to moderate protein expression was significantly associated with earlier tumor stage (p = 0.001) and less lymph node
involvement (p = 0.036). Interestingly, the patients with combined strong GRP78 and GRP94 protein expression exclusively
showed either early (pT1m or pT1sm) or advanced (pT3) tumor stages and no pT2 stage (p = 0.031).
Conclusion: We could demonstrate an association of GRP78 and GRP94 mRNA and protein expression with tumor stage and
behaviour in esophageal adenocarcinomas. Increased expression of GRP78 may be responsible for controlling local tumor
growth in early tumor stages, while high expression of GRP78 and GRP94 in advanced stages may be dependent from other
factors like cellular stress reactions due to glucose deprivation, hypoxia or the hosts' immune response.
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Background
The gluose-regulated proteins (GRPs) are members of the
endoplasmatic reticulum (ER) chaperone family, origi-
nally discovered as proteins inducible by glucose starva-
tion [1]. GRP78, also referred to as immunoglobulin
heavy chain binding protein (BiP) and GRP94, also
referred to as GP96, are central regulators of ER function
due to their roles in protein folding and controlling the
activation of transmembrane ER stress sensors. GRPs con-
trol normal physiological functions under moderate lev-
els of basal expression. Pathological conditions, such as
acidosis, hypoxia or hypothermia induce their up-regula-
tion[2].
The functions of GRPs suggest that they may also play
important roles in cancer biology and in the last years
knowledge about the association of GRPs and cancer has
increased: studies of GRPs have been performed with cells
in culture [3-7] and only a few studies were conducted
with human cancers, recently for breast cancer [8,9], pros-
tate cancer [10] or lung cancer for GRP78[11] and for lung
[12], colorectal [13] and esophageal squamous cell carci-
noma for GRP94 [14]. With a few exceptions there has
been the general observation that higher GRP78 and
GRP94 levels correlate with higher pathological grade and
aggressive behaviour. However, besides intratumoral or
intracellular conditions, the regulation of GRP expression
in tumor cells may be dependent from exposure to various
extratumoral stress factors like the potency of the immu-
nological answer of the host, hypoxia or cytotoxic treat-
ment[15], so that analysis of GRPs in human tumors as
well should consider those potential disturbing extrinsic
factors.
Adenocarcinoma of the esophagus shows a dramatically
increase in incidence during the whole 20th century, faster
than that of any other malignancy in Western countries.
Prognosis is poor with a 5-year survival generally less than
10% despite advances in diagnosis and therapy [16-20].
Consequently, many studies have investigated molecular
pathogenesis of this disease as progress with this malig-
nancy will only be made with an improved understanding
of this disease.
We now performed a study to analyze the expression of
GRP94 and GRP78 on mRNA and protein levels in
esophageal adenocarcinomas, in order to better under-
stand their impact in the biology of this entity and to
determine their potential prognostic implications. With
regard to the considerations mentioned above we aimed
to analyse a homogenous collective of patients and
selected primary resected tumors of 137 patients, who
were not treated by prior chemo- or radiochemotherapy.
Methods
Patients and specimens
Paraffin-embedded tumor samples of 137 patients with
primary resected esophageal adenocarcinoma from the
archives of the Institute of Pathology of the Technical Uni-
versity of Munich were investigated. According to the clas-
sification of Siewert and Stein all tumors were AEG type I
(adenocarcinoma of the distal esophagus)[21]. All
patients had undergone primary surgical resection (radi-
cal transthoracic or transhiatal esophagectomy with lym-
phadenectomy) at the Technical University of Munich.
The minimum follow-up time after surgery for surviving
patients was 42 months. Overall, the mean and medium
survival times were 45 months and 37 months, respec-
tively (range 3 to 164 months). None of the patients had
received neoadjuvant chemotherapy or radiochemother-
apy. Out of the 16 patients with positive resection mar-
gins, 7 patients recieved adjuvant radiotherapy.
Patients' approval was secured according to local arrange-
ments by the ethics committee (Ethikkommission der
Fakultät für Medizin der Technischen Universität
München, No. 1928/07). This study was performed with
patients' written consent allowing molecular research to
be performed on specimen obtained during surgical resec-
tion. The pT category and the pN category of the tumors
were determined according to the current TNM classifica-
tion[22], histological subtyping according to Lauren's
classification, tumor grading according to WHO classifica-
tion. Clinico-pathologic characteristics of the patients are
presented in Table 1.
Real-Time Quantitative Reverse-Transcriptase-
Polymerase Chain Reaction (RT PCR)
Microdissection, RNA extraction, cDNA synthesis and RT-
PCR were performed as described previously with minor
modifications[23]: From representative paraffin blocks of
tumor tissue or normal squamous epithelium two 10 µm
sections were deparaffinized (xylene for two times 10
min) and rehydrated (ethanol 100%/90%/70% ethanol
for 5 min each). Following short hemalaun staining, a
minimum of 2000 cells of defined carcinoma areas were
scraped off the glass slides with a sterile blade under light
microscopic control. Hemorrhagic or necrotic areas were
excluded and we aimed to obtain a high percentage of
tumor tissue compared to stromal components (at least
75%). The microdissected tumor tissue was transferred
into a sterile 1.5-ml tube containing RNA lysis buffer.
Lysis was carried out at 60°C for 24 hours until the tissue
was completely solubilized.
RNA was purified by phenol and chloroform extractions
followed by precipitation with an equal volume of isopro-
panol in the presence of 20 µl of 2 mol/L sodium acetate
(pH 4.0), and 2 µl of 10 mg/ml of carrier glycogen at -BMC Cancer 2008, 8:70 http://www.biomedcentral.com/1471-2407/8/70
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20°C. The RNA pellet was washed once in 70% ethanol,
dried and resuspended in 20 µl of RNase-free water.
10 µl of RNA was transcribed into cDNA by Superscript II
reverse transcriptase (Invitrogen) and 250 ng of random
hexamers (Roche, Penzberg, Germany) according to the
manufacturer's recommendations in a final volume of 20
µl. PCR reactions were performed in at least two replicates
with the Taq®Man Universal PCR Master Mix (15 µl,
Applied Biosystems, individual Taq®Man Gene Expression
Assays) by using 5 µl of diluted cDNA, 1 µl 200 nmol/L of
the labeled probe, and 1,5 µl pre-developed primer-probe
sets for GRP78 (Applied Biosystems assay ID
Hs99999174_m1) and GRP94 (Applied Biosystems assay
ID Hs00427665_g1) was used. Relative expression levels
of target genes were determined by the relative standard
curve method. Standard curves and line equations were
generated by using a standard cDNA solution from SW
480 colon carcinoma cell line (fresh frozen) which was
serially fivefold diluted and analyzed in duplicates for the
genes of interest and GAPDH as normalizing housekeep-
ing gene[24]. Based on the CT value and the correspond-
ing standard curve, the mRNA quantity of each sample
was calculated by determining the ratio between the
amounts of the gene of interest and GAPDH. Primers and
probe sequences for GAPDH are available from the
authors on request.
Immunohistochemical studies
Preparation of Tissue microarrays
From each of the 137 carcinomas one paraffin block was
selected and viable, representative areas of tumor speci-
mens were marked. Core needle biopsies were retrieved
from the original tumor blocks using a manual arrayer
(Beecher Instruments, Sun Prairie, WI) and positioned in
a recipient paraffin array block. We aimed at obtaining at
least three tissue cylinders per tumor with a diameter of
0.6 mm from each biopsy specimen.
Immunohistochemistry
Fresh 2 µm sections from TMA blocks were transferred to
glass slides, dewaxed and rehydrated. Antigen retrieval
methods were applied according to the manufacturers'
recommendations. The TMA slides were cooled and incu-
bated with the primary antibodies GRP78 (abcam, Cam-
bridge, UK) 0.20 mg/ml diluted at 1:100 and GRP94
(Santa Cruz Biotechnology Inc, CA), 0.20 mg/ml diluted
at 1:2000. The reaction was developed with the labelled
streptavidin-biotin-alkaline phosphatase system with fast
red used as the reaction indicator. After counterstaining
with hematoxylin, slides were dehydrated in ascending
concentrations of ethanol and mounted. Plasma cell
staining was used as internal positive control. Staining
was graded for intensity (1 = negative/weak; 2 = moderate;
3 = strong) and percentage of cells stained (1 = 0–10%; 2
= 10–50%; 3 = 50–100%) according to Lee et al[25] The
overall expression index was determined based on the fac-
tor of the previous variables and classified into one of the
following groups: negative/weak (1, 2), moderate (3, 4),
strong (6, 9).
Statistical analysis
SPSS statistical software was used for statistical analysis.
Relative gene expression levels were expressed in quartiles.
Associations in 2 × 2 tables were evaluated with Fisher's
exact test. Correlations were assessed by Pearson or Spear-
man correlation analyses. Comparison between groups
were performed using the student's T-test or by analysis of
variance. Survival analysis was performed using Kaplan-
Meier estimates, log rank tests and Cox's proportional
hazards regression analysis. All tests were 2-sided, and the
significance level was set at 5%.
Results
Gene Expression of GRP94 and GRP78mRNA
According to the selection criteria mentioned above
mRNA analyis was performed on tissue of 70 tumors and
10 probes of normal tissue. Quantitative real time-RT-
PCR analysis showed that GRP78 and GRP94 mRNA in
both cancer and normal tissues were easily detectable.
There was a significant, positive correlation between the
relative gene expression levels of GRP78 and GRP94 (p =
0.001; r = 0.404). Table 2 shows that expression levels of
Table 1: Clinicopathologic features of 137 patients with Barrett's 
adenocarcinoma included in this study.
Characteristics Data
Age
Mean 63
Range 33–83
Gender
Female 12 (9%)
Male 125 (91%)
pT category
pT1 64 (47%)
pT1m (mucosa) 28 (20%)
pT1sm (submucosa) 36 (26%)
pT2 25 (18%)
pT3 48 (35%)
pN category
pN0 82 (60%)
pN1 55 (40%)
Grade
11 2  ( 9 % )
26 1  ( 4 5 % )
36 4  ( 4 6 % )
Lauren's Classification
Intestinal 119 (87%)
Mixed 15 (11%)
Diffuse 3 (2%)BMC Cancer 2008, 8:70 http://www.biomedcentral.com/1471-2407/8/70
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GRP78 mRNA in early tumor stages were higher than in
normal esophageal squamous epithelium and in tumors
with advanced stages (p = 0.031), while GRP78 levels of
advanced tumors were not significantly different from
those in normal tissue. Furthermore, for GRP78, signifi-
cant higher mRNA levels were found in the well differen-
tiated tumors as compared to moderately and poorly
differentiated tumors (p = 0.035). In contrast, tumor
GRP94 mRNA levels were equal to normal esophageal
squamous epithelium in all stages and failed to show any
association to pathological features.
Immunohistochemistry
Neoplastic tissue was interpretable in 126 cases for GRP78
and in 127 cases for GRP94. Cytoplasmatic staining was
detectable in all tumors for both GRP78 and GRP94.
GRP78 and GRP94 expression correlated significantly
with each other (p = 0.029). Staining patterns are given in
Table 3 and in Figure 1. Normal squamous epithelium
showed moderate staining intensity for GRP78 and
GRP94 (see also Fig 1). With regard to pathological fea-
tures, there was a significant correlation between a strong
GRP78 expression and early tumor stages (pT1m and
pT1sm, p = 0.038). No correlation was found between
GRP78 expression and lymph node involvement or tumor
grade.
In contrast, for GRP94 low to moderate expression was
significantly associated with earlier tumor stage (p =
0.001) and less lymph node involvement (p = 0.036).
Tumor grade was not associated with GRP94 expression.
Correlation of mRNA-gene expression levels and 
immunohistochemistry
GRP78 mRNA expression showed a significant, positive
correlation with GRP78 protein-expression evaluated by
immunohistochemistry (p = 0.01). Particularly, patients
with a strong GRP78 protein expression showed signifi-
cant higher mRNA-levels than patients with low or mod-
erate gene expression levels (p < 0.001, see table 4).
Correlation between GRP94 mRNA gene expression levels
and GRP94 protein expression was notable but not signif-
icant (p = 0.19, see table 4).
Combined GRP78 and GRP94 expression
Combination of GRP78 and GRP94 gene expression lev-
els (both high GRP78/GRP94 expression levels vs. low
GRP78/GRP94 levels vs. mixed GRP78/GRP94 levels; cut
off: median gene expression level, see table 5.) did not
show any correlation with pathological parameters. How-
ever, the patients with both strong GRP78 and GRP94
protein expression exclusively showed either early (pT1m
or pT1sm) or advanced (pT3) tumor stages and no pT2
stage. Patients with combined low GRP78 and GRP94
expression had predominantly early tumor stages. Mixed
GRP78/GRP94 protein-expression was heterogenous with
more early tumor stages in patients with high GRP78/low
GRP94 expression and more advanced tumors in patients
with low GRP78/high GRP94 levels. (p = 0.031, see table
6.)
Survival correlations
For overall survival analysis patients with positive resec-
tion margins, distant metastasis at the time of surgery or
survival less than 1 month, were excluded. Univariate
analysis using time of death as the clinical end point
revealed high significant correlation of overall survival
and pT-category (HR = 1.446; CI = 1.20–2.44 p < 0.001)
and pN-category (HR = 2.773; CI = 1.36–3.21; p < 0.001)
and a trend towards better prognosis for patients with very
high GRP78 mRNA-levels (cut-off: 4th quartile, HR = 1.02;
CI = 0.990–1.029; p = 0.070) and for patients with high
GRP94 mRNA-levels (cut-off: median, HR = 0.016; CI =
0.974–1,059; p = 0.2). However, the prognostic impact of
high GPR78 and GRP94 levels was not independent from
pT-and pN-category in multiple regression analysis (see
fig. 2).
Table 2: Relative expression levels of GRP78 and GRP94 gene 
expression (mean+/-SW) and clinicopathologic features (gene/
GAPDH)
Group Cases GRP78/GAPDH GRP94/GAPDH
tissue
normal 10 0,53 ± 0,45 0,47 ± 0,61
carcinoma 70 0,96 ± 0,89* 0,43 ± 0,58
pT-category
pT1 41 1,15 ± 0,94§ 0,45 ± 0,55
pT1m 15 1,51 ± 1,08§§ 0,56 ± 0,73
pT1sm 26 0,95 ± 0,79 0,39 ± 0,43
pT2 13 0,60 ± 0,51 0,43 ± 0,83
pT3 15 0,62 ± 0,78 0,30 ± 0,35
pN-category
pN0 46 1,00 ± 0,89 0,38 ± 0,53
pN1 23 0,80 ± 0,83 0,49 ± 0,67
differentiation
G1 6 1,73 ± 1,00# 0,29 ± 0,28
G2 33 0,84 ± 0,89 0,48 ± 0,77
G3 26 0,82 ± 0,70 0,31 ± 0,27
* p = 0.022 vs. normal.
§ p = 0.042 vs. pT2 and pT3.
§§ p = 0.009 vs. pT2 and pT3.
# p = 0.035 vs. G2 and G3BMC Cancer 2008, 8:70 http://www.biomedcentral.com/1471-2407/8/70
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Immunohistochemical staining patterns of GRP78 and
GRP94 protein expression failed to show any correlation
with patient's survival, as well combined GRP78/GRP94
levels with survival.
Discussion
In the present study we examined GRP78 (BiP) and
GRP94 in primary resected adenocarcinomas of the
esophagus on mRNA gene expression level by quantitative
real time RT-PCR and on protein level by immunohisto-
chemistry. We found (a) a positive correlation between
the mRNA levels and the protein levels of GRP78 and
GRP94, (b) higher GRP78 mRNA and protein expression
levels in early tumor stages and tumors of higher differen-
tiation grades, and (c) in contrast to that an association
between high GRP94 protein expression and advanced
tumor stage and lymph node involvement. Interestingly,
in the group of patients with combined strong GRP78 and
GRP94 protein expression levels, an association with
either early (pT1) or advanced (pT3) tumor stages, while
patients with pT2 tumors showed moderate GRP78 and
GRP94 protein expression levels.
GRP78 (BiP) and GRP94 are the best studied members of
the family of glucose-regulated proteins (GRPs). GRP94
and GRP78 are found constitutively within the ER and
perform normal physiological functions under moderate
levels of basal expression. Because of their ability to assist
in protein folding and assembly, the GRPs are referred to
as molecular chaperones[26]. They were first described as
a set of proteins whose synthesis was enhanced when cells
were deprived of glucose[1,2]. In tumor cells, besides
hypoxic acidic or above mentioned glucose starvation
conditions, the induction of GRP94 or GRP78 may also
represent a defence mechanism for the survival of cancer
cells exposed to these stress conditions or to the immuno-
logical response of the host[15,27,28].
Most studies of GRPs induction in tumors first have been
conducted with animal models or cells in culture like
breast cancer[4,25] or colorectal[29,30] cancer cell lines
where correlated regulation of GRP78 and GRP94 gene
expression was reported confirming our findings. Only
one study deals with esophageal adenocarcinoma in rats
and very few samples of human carcinomas[31]. In other
human cancers, there has been the general observation
that higher GRP78 and GRP94 levels correlate with higher
pathological grade and aggressive behaviour in
breast[8,9,32], liver[33], colon[13,34] and prostate[10]
carcinomas. A study dealing with esophageal squamous
cell carcinomas describes a higher GRP94 protein-expres-
sion in carcinomas compared to normal esophageal
mucosa without further correlation to pathological char-
acteristics [14]. In contrast, for lung cancer[11] there are
conflicting reports on this association and one study dem-
onstrates an association between high GRP78 levels and
Table 3: Immunohistochemical results for GRP78 and GRP94
Group GRP78 (n = 126) GRP94 (n = 127)
negative/weak moderate strong negative/weak moderate strong
t o t a l 4 96 1 1 6 1 56 1 5 1
pT-cat.
pT1 26 27 10* 9§ 35§ 15
p T 1 m 81 0 5 21 2 6
p T 1 s m 1 8 1 75 7 2 39
pT2 13 8 1 4 10 9
pT3 10 26 4 2 16 25
pN-cat.
pN0 27 37 10 8§§ 40§§ 22
pN1 22 24 5 7 20 27
differentiation
G1 2 3 3 1 6 2
G2 17 25 6 7 25 24
G3 23 25 3 7 29 23
* p = 0.038 for pT stage and strong vs. low to moderate GRP78 expression.
§ p = 0.001 for pT stage and low to moderate vs. strong GRP94 expression.
§§ p = 0.036 for pN stage and low to moderate vs. strong GRP94 expressionBMC Cancer 2008, 8:70 http://www.biomedcentral.com/1471-2407/8/70
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good prognosis concordant to our findings for esophageal
adenocarcinomas[12]. The discrepancies between our
results and others may reflect a different GRP regulation
depending from the tumor type or the heterogeneity of
the investigated tumor collectives.
Another interesting finding of our analysis was that high
GRP78 gene and protein expression was found in early
stages of esophageal adenocarcinoma and in a small pro-
portion of patients with advanced tumor stages high
GRP78 protein expression also could be detected. High
GRP94 protein expression exclusively was associated with
Table 4: Correlation between GRP78 and GRP94 gene expression and immunohistochemistry
Cases staining gene-expression level (mean ± SW)
GRP78 22 negative/weak 0,75 ± 0,75
35 moderate 0,75 ± 0,77
9 strong 2,74 ± 1,62*
GRP94 6 negative/weak 0,12 ± 0,09
36 moderate 0,41 ± 0,41
18 strong 0,64 ± 0,93
* p < 0.001 vs. Negative/weak and moderate
Immunohistochemical staining for GRP78 and GRP94 in esophageal adenocarcinoma Figure 1
Immunohistochemical staining for GRP78 and GRP94 in esophageal adenocarcinoma.A Weak expression of 
GRP78; B Strong expression of GRP78; C moderate expression of GRP78 in normal squamous epithelium (left side) and ade-
nocarcinoma (right side); D weak expression of GRP94; E strong expression of GRP94; F moderate expression of GRP94 in 
normal squamous epithelium. (20×).BMC Cancer 2008, 8:70 http://www.biomedcentral.com/1471-2407/8/70
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advanced tumor stages and patients with pT2 tumors
showed moderate GRP78 and GRP94 levels. This observa-
tion may be explained by different mechanisms of GRP
regulations: overexpression that occurs in early stages of
disease may represent a reaction to an early response of
the host's immune system, while upregulation in
advanced stages may be related to different stress facors
like glucose starvation, hypoxia or also immune reactions
towards the tumor[35]. Furthermore, there are reports
that show that the induction of GRP78/GRP94 at the pro-
tein level is not always corresponding with the transcript
level[4]. So increased protein expression that fails to cor-
relate with gene expression level – like in our study for
GRP78 and GRP94 in advanced tumor stages- may be
related to posttranslational regulations or modifications
like activating or inactivating phosphorylation or glyco-
sylation [36].
Another aspect that may draw attention to the role of
GRPs in human cancers is the relationship between induc-
tion of GRPs and tumor resistance against chemotherapy
(CTX) treatment, as reported very recently for breast [25]
and prostate[37] cancer, where high GRP78 expression
was associated with tumor resistance to CTX. However,
influence of CTX on GRP expression and vice versa was
not topic of our investigations. In this first study about
GRPs in – to our knowledge – the largest series of human
esophageal adenocarcinomas so far, we aimed to investi-
gate GRP expression in tumors without disturbing influ-
ences of cytotoxic treatment as it strongly may influence
the expression of GRPs. So we selected only patients with
primary resected tumors, without prior chemo- or radio-
chemotherapy (RCTX) – the few patients with postopera-
tive radiation therapy due to positive resection margins
were excluded for survival analysis. Thereby we achieved
knowledge about the biology of GRPs in untreated
esophageal adenocarcinomas and their partly heteroge-
nous expression patterns even in conditions without the
presumably strong influence CTX/RCTX. These findings
are essential informations for forthcoming studies dealing
with the interaction of CTX/RCTX and GRP expression.
Conclusion
In summary, by analysing the expression of Glucose-
related proteins (GRPs) in primary resected human aden-
ocarcinomas on mRNA gene expression level and on pro-
tein level we could demonstrate an association with
tumor stage and behaviour. Our findings may help to bet-
ter understand the complex mechanisms of cancer biol-
ogy, immunology and tumor response to stress
conditions reflected by increased GRP activation. They
may serve as basis for studies that also could direct
towards analyzing whether sensitivity or resistance to
chemotherapeutic or other antitumoral drugs is associ-
ated with increased or decreased expression of GRPs in
tumor cells and therefore help to improve individualized
cancer treatment.
Table 5: Combined GRP78 and GRP94 relative gene expression levels (gene/GAPDH) and pT-category
Group high GRP78/high GRP94 high GRP78/low GRP94 low GRP78/high GRP94 low GRP78/low GRP94
total 23 11 11 24
pT cat.
pT1 18 7 6 10
pT2 3 2 1 7
pT3 2 2 4 7
p = 0.197 (X2-test)
Table 6: Immunohistochemical results for combined GRP78 and GRP94 and pT-category
Group high GRP78/high GRP94 high GRP78/low GRP94 low GRP78/high GRP94 low GRP78/low GRP94
total 6 9 35 62
pT cat.
pT1 3 7 9 34
pT2 0 1 8 12
pT3 3 1 18 16
p = 0.031 (X2-test)BMC Cancer 2008, 8:70 http://www.biomedcentral.com/1471-2407/8/70
Page 8 of 9
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
RL conceived of the study, carried out assembly of tissue
micro arrays and evaluation of immunohistochemical
stainings and of RT-PCR data, and was involved in prepa-
ration of the manuscript. MF and JS participated in the
design of the study and were responsible for collection of
clinical data. HW participated in the design of the study
and coordination and helped to draft the manuscript. HH
conceived of the study, and participated in its design and
coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We thank Mrs. Andrea Bruetting and Mrs. Andrea Hawarth for expert 
technical assistance performing the laboratory work. The study was sup-
ported by Deutsche Krebshilfe, Grant Nr. 70-2789 and the Bavarian State 
Ministry of Sciences, Research and the Arts (BayGene Program)
References
1. Lee AS: The glucose-regulated proteins: stress induction and
clinical applications.  Trends Biochem Sci 2001, 26(8):504-510.
2. Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS: The glucose-reg-
ulated proteins (GRP78 and GRP94): functions, gene regula-
tion, and applications.  Crit Rev Eukaryot Gene Expr 1994, 4(1):1-18.
3. Dey A, Kessova IG, Cederbaum AI: Decreased protein and
mRNA expression of ER stress proteins GRP78 and GRP94
in HepG2 cells over-expressing CYP2E1.  Arch Biochem Biophys
2006, 447(2):155-166.
4. Gazit G, Lu J, Lee AS: De-regulation of GRP stress protein
expression in human breast cancer cell lines.  Breast Cancer Res
Treat 1999, 54(2):135-146.
5. Miyake H, Hara I, Arakawa S, Kamidono S: Stress protein GRP78
prevents apoptosis induced by calcium ionophore, ionomy-
cin, but not by glycosylation inhibitor, tunicamycin, in
human prostate cancer cells.  J Cell Biochem 2000, 77(3):396-408.
6. Qian Y, Harris ED, Zheng Y, Tiffany-Castiglioni E: Lead targets
GRP78, a molecular chaperone, in C6 rat glioma cells.  Toxicol
Appl Pharmacol 2000, 163(3):260-266.
7. Sun S, Han J, Ralph WM Jr., Chandrasekaran A, Liu K, Auborn KJ,
Carter TH: Endoplasmic reticulum stress as a correlate of
cytotoxicity in human tumor cells exposed to diindolylmeth-
ane in vitro.  Cell Stress Chaperones 2004, 9(1):76-87.
8. Melendez K, Wallen ES, Edwards BS, Mobarak CD, Bear DG, Moseley
PL: Heat shock protein 70 and glycoprotein 96 are differen-
tially expressed on the surface of malignant and nonmalig-
nant breast cells.  Cell Stress Chaperones 2006, 11(4):334-342.
9. Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN,
Schwartz AM, Kennedy KA, Patierno SR: Overexpression of the
glucose-regulated stress gene GRP78 in malignant but not
benign human breast lesions.  Breast Cancer Res Treat 2000,
59(1):15-26.
10. Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH, Ste-
venson MA, Calderwood SK: Expression of heat shock proteins
and heat shock protein messenger ribonucleic acid in human
prostate carcinoma in vitro and in tumors in vivo.  Cell Stress
Chaperones 2005, 10(1):46-58.
11. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T,
Morita M, Yasumoto K: Expression of endoplasmic reticulum
molecular chaperone Grp78 in human lung cancer and its
clinical significance.  Lung Cancer 2005, 49(1):55-62.
12. Wang Q, He Z, Zhang J, Wang Y, Wang T, Tong S, Wang L, Wang S,
Chen Y: Overexpression of endoplasmic reticulum molecular
chaperone GRP94 and GRP78 in human lung cancer tissues
and its significance.  Cancer Detect Prev 2005, 29(6):544-551.
13. Wang XP, Qiu FR, Liu GZ, Chen RF: Correlation between clinico-
pathology and expression of heat shock protein 70 and glu-
cose-regulated protein 94 in human colonic
adenocarcinoma.  World J Gastroenterol 2005, 11(7):1056-1059.
14. Wang XP, Liu GZ, Song AL, Chen RF, Li HY, Liu Y: Expression and
significance of heat shock protein 70 and glucose-regulated
protein 94 in human esophageal carcinoma.  World J Gastroen-
terol 2005, 11(3):429-432.
15. Lee AS: GRP78 induction in cancer: therapeutic and prognos-
tic implications.  Cancer Res 2007, 67(8):3496-3499.
16. von Rahden BH, Stein HJ, Siewert JR: Barrett's esophagus and
Barrett's carcinoma.  Curr Oncol Rep 2003, 5(3):203-209.
17. Stein HJ, Feith M, Siewert JR: Cancer of the esophagogastric
junction.  Surg Oncol 2000, 9(1):35-41.
18. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt
PA: Trends in incidence of adenocarcinoma of the oesopha-
gus and gastric cardia in ten European countries.  Int J Epide-
miol 2000, 29(4):645-654.
19. van Sandick JW, van Lanschot JJ, Tytgat GN, Offerhaus GJ, Obertop
H: Barrett oesophagus and adenocarcinoma: an overview of
epidemiologic, conceptual and clinical issues.  Scand J Gastroen-
terol Suppl 2001:51-60.
20. Pera M: Epidemiology of esophageal cancer, especially aden-
ocarcinoma of the esophagus and esophagogastric junction.
Recent Results Cancer Res 2000, 155:1-14.
21. Siewert JR, Stein HJ: Classification of adenocarcinoma of the
oesophagogastric junction.  Br J Surg 1998, 85(11):1457-1459.
22. Sobin LH Wittekind, Ch, eds. UICC: TNM classification of malig-
nant tumours.  New York , John Wiley & Sons; 2002. 
23. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H: Quan-
titative gene expression analysis in microdissected archival
formalin-fixed and paraffin-embedded tumor tissue.  Am J
Pathol 2001, 158(2):419-429.
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De
Paepe A, Speleman F: Accurate normalization of real-time
quantitative RT-PCR data by geometric averaging of multi-
ple internal control genes.  Genome Biol 2002,
3(7):RESEARCH0034.
25. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS: GRP78 as a
Novel Predictor of Responsiveness to Chemotherapy in
Breast Cancer.  Cancer Res 2006, 66(16):7849-7853.
26. Mavropoulos JC, Fields TA, Pizzo SV: Chaperones and disease.  N
Engl J Med 2005, 353(26):2821-2; author reply 2821-2.
GRP78 levels in esophgeal adenocarcinoma and survival Figure 2
GRP78 levels in esophgeal adenocarcinoma and sur-
vival.
140,00 120,00 100,00 80,00 60,00 40,00 20,00 0,00
months after surgery
1,0
0,8
0,6
0,4
0,2
0,0
e
s
t
i
m
a
t
e
d
 
p
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
High GRP78 levels
Low and moderate GRP78 levels 
p=0.07 Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:70 http://www.biomedcentral.com/1471-2407/8/70
Page 9 of 9
(page number not for citation purposes)
27. Fu Y, Lee AS: Glucose regulated proteins in cancer progres-
sion, drug resistance and immunotherapy.  Cancer Biol Ther
2006, 5(7):741-744.
28. Li J, Lee AS: Stress induction of GRP78/BiP and its role in can-
cer.  Curr Mol Med 2006, 6(1):45-54.
29. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa
Y, Tsuruo T, Shin-ya K: Effect on tumor cells of blocking survival
response to glucose deprivation.  J Natl Cancer Inst 2004,
96(17):1300-1310.
30. Park HR, Ryoo IJ, Choo SJ, Hwang JH, Kim JY, Cha MR, Shin-Ya K,
Yoo ID: Glucose-deprived HT-29 human colon carcinoma
cells are sensitive to verrucosidin as a GRP78 down-regula-
tor.  Toxicology 2007, 229(3):253-261.
31. Chen X, Ding Y, Liu CG, Mikhail S, Yang CS: Overexpression of
glucose-regulated protein 94 (Grp94) in esophageal adeno-
carcinomas of a rat surgical model and humans.  Carcinogenesis
2002, 23(1):123-130.
32. Neubauer H, Clare SE, Kurek R, Fehm T, Wallwiener D, Sotlar K,
Nordheim A, Wozny W, Schwall GP, Poznanovic S, Sastri C, Hunz-
inger C, Stegmann W, Schrattenholz A, Cahill MA: Breast cancer
proteomics by laser capture microdissection, sample pool-
ing, 54-cm IPG IEF, and differential iodine radioisotope
detection.  Electrophoresis 2006, 27(9):1840-1852.
33. Lim SO, Park SG, Yoo JH, Park YM, Kim HJ, Jang KT, Cho JW, Yoo
BC, Jung GH, Park CK: Expression of heat shock proteins
(HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis
B virus-related hepatocellular carcinomas and dysplastic
nodules.  World J Gastroenterol 2005, 11(14):2072-2079.
34. Xing X, Lai M, Wang Y, Xu E, Huang Q: Overexpression of glu-
cose-regulated protein 78 in colon cancer.  Clin Chim Acta 2006,
364(1-2):308-315.
35. Ciocca DR, Calderwood SK: Heat shock proteins in cancer:
diagnostic, prognostic, predictive, and treatment implica-
tions.  Cell Stress Chaperones 2005, 10(2):86-103.
36. Ni M, Lee AS: ER chaperones in mammalian development and
human diseases.  FEBS Lett 2007, 581(19):3641-3651.
37. Pootrakul L, Datar RH, Shi SR, Cai J, Hawes D, Groshen SG, Lee AS,
Cote RJ: Expression of stress response protein Grp78 is asso-
ciated with the development of castration-resistant prostate
cancer.  Clin Cancer Res 2006, 12(20 Pt 1):5987-5993.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/70/prepub